Hospital -based or home -based administration of oncology drugs? A micro -costing study comparing healthcare and societal costs of hospital -based and home -based subcutaneous administration of trastuzumab

被引:15
作者
Franken, Margreet [1 ,2 ]
Kanters, Tim [1 ,2 ]
Coenen, Jules [3 ]
de Jong, Paul [4 ]
Jager, Agnes [5 ]
Uyl-de Groot, Carin [1 ,2 ]
机构
[1] Erasmus Univ, Inst Med Technol Assessment, POB 1738, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands
[3] Isala, Dept Oncol, Zwolle, Netherlands
[4] St Antonius Hosp, Dept Internal Med, Utrecht, Netherlands
[5] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
关键词
Breast cancer; Healthcare costs; Home-based; Hospital-based; Injection; Micro-costing; Netherlands; Resource use; Societal costs; Subcutaneous; Trastuzumab; BREAST-CANCER; INTRAVENOUS TRASTUZUMAB; RESOURCE UTILIZATION;
D O I
10.1016/j.breast.2020.05.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate resource use and time investments of healthcare professionals, patients and their family and to compare healthcare and societal costs of one single hospital-based and one single home-based subcutaneous administration of trastuzumab in The Netherlands. Method: We conducted a bottom-up micro-costing study. Patients diagnosed with HER2+ early or metastatic breast cancer were recruited in four Dutch hospitals. For healthcare costs, data were collected on drug use, consumables, use of healthcare facilities, time of healthcare professionals, and travelling distance of the nurse. For societal costs, data were collected on patient and family costs (including travelling expenses and time of informal caregivers) and productivity losses of paid and unpaid work. Results: Societal costs of one single administration of SC trastuzumab were (sic)1753 within the home- based and (sic)1724 within the hospital-based setting. Drug costs of trastuzumab were identical in both settings ((sic)1651). Healthcare costs were higher for home-based administration ((sic)91 versus (sic)47) mainly because of more time of healthcare professionals (110 versus 38 minutes). Costs for patient and family were, however, lower for home-based administration due to travelling expenses ((sic)7 versus (sic)0) and time of informal caregivers ((sic)14 versus (sic)4). Costs for productivity losses were similar for both settings. Conclusions: Home-based subcutaneous administration of trastuzumab is more time consuming for healthcare professionals and therefore more costly than hospital-based administration. The total budget impact can be large considering that a large number of patients receive a large number of cycles of oncology treatments. If home-based administration is the way forward, novel approaches are crucial for ensuring ef ficiency of home-based care. (C) 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
引用
收藏
页码:71 / 77
页数:7
相关论文
共 20 条
[1]  
[Anonymous], 2018, DUTCH HOSP FIGURES
[2]  
[Anonymous], 2018, DO PAT PREF HOM BAS
[3]   The friction-cost method - Replacement for nothing and leisure for free? [J].
Brouwer, WBF ;
Koopmanschap, MA .
PHARMACOECONOMICS, 2005, 23 (02) :105-111
[4]  
Burcombe R., 2013, Adv. Breast Cancer Res, V02, P133, DOI [DOI 10.4236/ABCR.2013.24022, 10.4236/abcr.2013.24022]
[5]   Organization, quality and cost of oncological home-hospitalization: A systematic review [J].
Cool, Lieselot ;
Vandijck, Dominique ;
Debruyne, Philip ;
Desmedt, Melissa ;
Lefebvre, Tessa ;
Lycke, Michelle ;
De Jonghe, Pieter Jan ;
Pottel, Hans ;
Foulon, Veerle ;
Van Eygen, Koen .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 126 :145-153
[6]   The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data [J].
Desgagne, A ;
Castilloux, AM ;
Angers, JF ;
LeLorier, J .
PHARMACOECONOMICS, 1998, 13 (05) :487-497
[7]  
European Medicines Agency, 2013, EMEAHC000278
[8]   Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands [J].
Franken, Margreet G. ;
Kanters, Tim A. ;
Coenen, Jules L. ;
de Jong, Paul ;
Koene, Harry R. ;
Lugtenburg, Pieternella J. ;
Jager, Agnes ;
Uyl-de Groot, Carin A. .
ANTI-CANCER DRUGS, 2018, 29 (08) :791-801
[9]  
Hakkaart-van Roijen L, 2015, DUTCH KOSTENHANDLEID
[10]  
Jackisch C, 2014, ANN ONCOL, V26, P320